tbuckley/cabot-search huggingface dataset:
PTU-053 Metachronous Extra-Colonic Malignancy in Collagenous Colitis
Authors: KJ Dabos, DE Yung, A Giannakou, M MacNeill, P Fineron, J Plevris, A Koulaouzidis
Journal: Gut (2016)

<h3>Introduction</h3> Collagenous colitis (CC) is a syndrome of chronic, watery, non-bloody diarrhoea.<sup>1</sup> Its worldwide incidence is increasing; emerging evidence suggests a possible association between CC and malignancy.<sup>2</sup> However, studies thus far have been inconclusive and data on the incidence of metachronous extra-colonic malignancy (MEcM) in CC is scarce.<sup>3</sup> This study aimed to determine the occurrence of MEcM in patients with CC. <h3>Methods</h3> Retrospective study; data on MEcM in patients previously diagnosed with CC was collected within NHS Lothian (Scotland) over a 14 year period (Jan 2000 – Nov 2013). Person-years at risk were calculated according to age-specific categories. The standard error (<i>Se</i>) was calculated using the <i>Poisson </i>approximation. Relative risk (<i>RR</i>) and confidence interval (<i>CI</i>) of the age-standardised rate (<i>ASR</i>) were compared to publicly available population data for Lothian, Scotland.<sup>4</sup> Results are reported as average ± standard deviation or <i>RR</i> with confidence interval (CI). <i>P</i> values &lt;0.05 were considered statistically significant. <h3>Results</h3> In the aforementioned period, 394 patients were diagnosed with CC and included for analysis. Thirty-three (21 F/12 M) developed MEcM, <b><i>Table 1</i></b>. The average age of the group with MEcM was 71.6 ±7.4 years compared to 65.9 ±13.6 years for the remainder of the patients (<i>P</i> &lt; 0.05). The average duration of follow-up from CC diagnosis to MEcM was 2 ±2.23 years and for the group as a whole was 4 ±3.45 years. The <i>RR</i> for lung cancer (4.63, 1.30;16.49) and total cancers (2.34, 1.38;3.95) in patients with CC was higher compared to population data from Lothian (<i>P</i> &lt; 0.05 for both). <h3>Conclusion</h3> The RR of MEcM, including lung cancer, is higher in patients with CC.The increased RR for lung cancer may be explained by the association between CC and smoking.<sup>5</sup> Further collective data will be useful to clarify other associations. <h3>References</h3> 1 Münch A, <i>et al</i>. Microscopic colitis: current status, present and future challenges: statements of the European Microscopic Colitis Group. <i>J Crohn's Colitis</i> 2012;<b>6</b>:932–945. 2 Freeman HJ. Complications of collagenous colitis. <i>World J gastroenterol</i> 2008;<b>14</b>:1643. 3 Chan JL, <i>et al</i>. Cancer risk in collagenous colitis. <i>Inflamm Bowel Dis</i> 1999;<b>5</b>:40–43. 4 http://www.ncin.org.uk/cancer_information_tools/eatlas/guide 5 Vigren L, <i>et al</i>. Is smoking a risk factor for collagenous colitis? <i>Scand J Gastroenterol</i> 2011;<b>46</b>:1334–1339. <h3>Disclosure of Interest</h3> None Declared
AB0941 Systematic Literature Review of Ultrasound in Large Vessel Vasculitis for Establishing Omeract Definitions
Authors: C. Duftner, C. Dejaco, A. Iagnocco, W.A. Schmidt
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Ultrasound (US) is increasingly used for the diagnosis of large vessel vasculitis (LVV), as this imaging technique enables the visualization of the inflammatory vessel wall swelling. A consensus about the definition of US lesions for diagnosis of LVV has not yet been accomplished. <h3>Objectives</h3> 1) To identify definitions of US lesions in LVV; 2) to evaluate the role of US in monitoring disease response; and 3) to assess the value of identified US lesions for diagnosis of LVV. <h3>Methods</h3> A systematic literature search was conducted in PubMed, Embase and the Cochrane Library (till 23rd November 2014). Research articles enrolling at least 20 patients with suspected cranial giant cell arteritis (GCA) or large-vessel GCA (LV-GCA), Takayasu arteritis (TAK), published in English or German were selected. The study design, subjects, methods, imaging protocols and diagnostic values were evaluated, as well as the US definitions of vasculitis. The quality of the included studies was assessed by the QUADAS2 tool. <h3>Results</h3> Of 2960 articles identified, 34 studies were included in the review for the extraction of definitions of vasculitis in US. Thirty-two reports addressed the role of US in diagnosis of cranial GCA, whereas only 6 studies evaluated US in the settings of LV-GCA. The role of US in disease monitoring was evaluated in 11 articles on cranial GCA and in 2 articles on LV-GCA. No studies assessing the role of US in TAK fulfilled the inclusion criteria. Most studies investigated the value of the “halo sign” (32 articles), whereas “compression sign”, “stenosis”, “occlusion” or “decreased vessel wall pulsation” as signs of vasculitis were addressed in 1, 22, 19, and 1 paper(s), respectively. <h3>Conclusions</h3> US is a valuable diagnostic tool in patients with suspected GCA. In this systematic literature review we identified “halo sign”, “stenosis”, “occlusion”, “compression sign” and a “decreased vessel wall pulsation” as possible key US lesions for vasculitis. Based on these results future research on the role of US in LVV is now being performed by the OMERACT US group. <h3>Disclosure of Interest</h3> None declared
THU0416 Prevalence of Comorbidities and Risk Factors in Spondyloarthritis in Latin America: A Comparative Study with General Population: Data from The Multinational Asas-Comospa Study
Authors: W. Bautista-Molano, R. Landewé, A. Moltό, R. Burgos-Vargas, J. Maldonado-Cocco, R. Valle-Oñate, D. van der Heijde
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Increased risk of some comorbidities has been reported in spondyloarthritis (SpA). Knowledge about the prevalence and data related to these comorbidities and risk factors in Latin America is limited. <h3>Objectives</h3> To determine the prevalence of several comorbidities and risk factors for these comorbidities in patients with SpA in three Latin American countries, and to compare this prevalence with the rates in the general population investigating whether the prevalence is increased. <h3>Methods</h3> Data of 390 consecutive patients with SpA enrolled in the international cross-sectional ASAS-COMOSPA study from Argentina, Colombia and Mexico were analysed. The prevalence rates (95% CI) of arterial hypertension (AHT), tuberculosis (TB), and malignancies (colon, melanoma, lung, lymphoma, prostate, cervix and breast) were estimated with continuity correction according to the method described by Wilson. The data from Colombian general population (adjusted per gender and age group) were obtained from the CARMELA study for AHT, from the National Health Surveillance Public System for TB and HBV and from the GLOBOCAN project for malignancies. The prevalence (95% IC) in SpA patients was compared with the prevalence rates in the Colombian general population by calculating age and gender-specific prevalences for AHT, TB and HBV, and calculating gender-specific prevalences for malignancies. SPSS Statistics 22 was used to perform the statistical analysis. <h3>Results</h3> In total 64% were male, mean age of 45 (14.7) years and disease duration of 7.0 (8.1) years. The most common comorbidities were AHT (25.3%), hypercholesterolemia (21.8%), osteoporosis (9.4%) and gastrointestinal ulcer (7.8%). The prevalence of AHT was 25.3% (95% CI 21.2 to 29.4) and was significantly higher compared with the general population 13.4% (95% CI 11.5 to 15.2). The overall prevalence of TB was 3.33% (95% CI 1.8 to 5.7) and the prevalence of HBV infection was 1.03% (95% IC 0.3 to 2.7), both increased as compared with the general population (0.03% and 0.01% respectively). There was not an increased prevalence of cancers compared with general population. <h3>Conclusions</h3> In patients with SpA, we found a higher prevalence of hypertension, tuberculosis and hepatitis B infections in three Latin America countries as compared with general population data. A systematic evaluation and screening of these comorbidities and risk factors may help to properly monitor and detect these conditions in SpA patients. <h3>References</h3> Molto A, et al. Ann Rheum Dis 2015 Oct 21 pii: annrheumdis-2015–208174 Gherghe AM, et al. RMD Open 2015 Sept 14;1(1):e000128 Hernández-Hernández R, J Hypertens 2010, 28:24–34 <h3>Disclosure of Interest</h3> None declared
Haematopoietic Stem Cell Transplantation in Thalassaemic Patient with Renal Failure on Hemodialysis
Authors: Francesca Argiolu, Maria Adele Sanna, Antonella Bartoli, Rocco Ferrara, Antonio Piroddi, Carmen Addari, Maria Grazia Orofino, Fabiana Rizzo, Fausto Cossu, Maria Rosa Scalas, Monica Broglia, Nicolina Giagu, Renzo Galanello
Journal: Blood (2008)
Induction with an Oral Chemotherapy-Cyclophosphamide in Combination with Idarubicin and Dexamethasone (CID) Followed by Early Autologous Stem Cell Transplantation for Multiple Myeloma Patients.
Authors: Nalini K. Pati, Yiu-Lam Kwan, Arumugam Manoharan, Michael Teh
Journal: Blood (2006)
O-009 NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate
Authors: J. Strosberg, E. Wolin, B. Chasen, M. Kulke, D. Bushnell, M. Chaplin, R. Baum, P. Kunz, T. Hobday, K. Oberg, M. Lopera Sierra, D. Kwekkeboom, P. Ruszniewski, E. Krenning, A. Hendifar
Journal: Annals of Oncology (2016)
AB0921 Infectious Spondylodiscitis Features: about 44 Cases
Authors: R. Dhahri, I. Gharsallah, N. Boussetta, R. Abid, L. Metoui, F. Laajili
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Spinal infections can be described aetiologically as pyogenic, granulomatous (tuberculous, brucellar, fungal) and parasitic. Its early diagnosis is crucial to the establishment of adequate treatment in order to get favorable outcomes. The aim of the present work was to describe clinical, diagnostic and therapeutic aspects of Infectious Spondylodiscitis according to the experience of an internal medicine department in Tunisia. <h3>Methods</h3> Patients with SDI either confirmed or presumed and hospitalized in the internal medicine department of The Principle Military Hospital Of Tunis, Tunisia have been included in the Study. <h3>Results</h3> Fourty-four patients met the inclusion criteria. They have been gathered over 20 years-period. They were 24 men and 20 women with an average age at 52.5 years. The diagnosis was a Tuberculous Spondylodiscitis in 22 cases (50%): among them 10 patients had a concomitant extra spinal TB. The diagnostic delay was 231 days for TB SDI and 40.5 days for SDP. Revealing symptoms were dominated by pain:, often mixed (61%). Radicular pain was noted in 15 cases. Fever was found in 17 cases. On examination: spinal syndrom was present in 65.9% of cases, spinal cord compression signs were found in 8 patients. MRI was contributive in all cases showing a disc enhancement in 50% (SDP in 67%, TSDI in 33%), epiduritis in 63.5% (SDP 60%, TSDI 67%). The disc biopsy was contributive in 71% of cases. The diagnosis was certain in 15 cases, highly probable in 18 cases and presumptive in 11 cases. Treatment duration was 13 months for SDT and 18 weeks for SDP. The outcome was favorable in 30 cases (SDP 13, TSDI 17). <h3>Conclusions</h3> Infectious sondylodiscitis remains a diagnostic and therapeutic problem in our country. Only an early care can enhance its prognosis. <h3>Disclosure of Interest</h3> None declared
Dominant NFKB1 Mutations Cause Antibody Deficiency and Autoinflammatory Episodes
Authors: Emma M Haapaniemi, Meri Kaustio, Helka Nurkkala, Merja Helminen, Satu Mustjoki, Einarsdottir Elisabet, Sahu Biswajyoti, Sanna Kilpinen, Jaana Syrjänen, Samuli Rounioja, Christopher Fogarty, Virpi Glumoff, Petri Kulmala, Shintaro Katayama, Fitsum Tamene, Timi Martelius, Luca Trotta, Ekaterina Morungova, Jussi Taipale, Janna Saarela, Juha Kere, Markku Varjosalo, Mikko Seppänen
Journal: Blood (2015)
AB0281 Body Image Disturbance in Patients with Rheumatoid Arthritis Who Requires Surgical Intervention
Authors: M. Horita, D. Kaneda, A. Takeshita, T. Machida, R. Nakahara, Y. Nasu, K. Hashizume, K. Nishida, T. Ozaki
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Recent effective treatment with disease-modifying anti-rheumatic drugs (DMARDs) including biologic DMARDs (bDMARDs) improved the disease control of patients with rheumatoid arthritis (RA), and the change of body image of the patients might influenced the surgical indication. Body image assessment tool (BIAT) has been reported to be a reliable and valid tool<sup>1)</sup>. Patients with RA had a worse body image than individuals without RA<sup>2)</sup>, however, there are no evidence showed the body image of patients who requires surgical intervention. <h3>Objectives</h3> The current study aimed to investigate the body image of patients who requires surgical intervention and to examine the correlation with depressive condition. <h3>Methods</h3> 163 patients (16 male, 147 female) with RA were divided into two groups of patients who didn9t require the surgical intervention (non-operative group) and who underwent surgery (operative group). The non-operative group and operative group included 88 and 75 patients, respectively. The mean age of the non-operative and operative group were 64.8 and 64.4 years, and the mean disease duration were 17.5 and 22.7 years, respectively. The clinical evaluation included the use of bDMARDs, pain VAS (0–100mm), Health Assessment Questionnaire Disability Index (HAQ-DI), disease activity (DAS28-CRP), depression assessed by Beck Depression Inventory-II (BDI-II), and body image assessed by BIAT. Statistical analyses were performed using the Mann-Whitney U test, and Fisher9s exact test. <h3>Results</h3> The rate of use of bDMARDs was not significant between non-operative and operative group. In the operative group, pain VAS, HAQ-DI, DAS28-CRP and BDI-II were significantly higher (p&lt;0.01, p&lt;0.01, p&lt;0.01 and p=0.02, respectively) and BIAT was significantly lower (p=0.02) when compared with non-operative group. Higher BDI-II significantly correlated with lower BIAT in both non-operative (r=-0.69, p&lt;0.01) and operative group (r=-0.61, P&lt;0.01). <h3>Conclusions</h3> The result of this survey found the body image of patients in operative group was disturbed than that of non-operative patients. Body image disturbance was highly correlated with depressive condition in both operative and non-operative patients. To assess the body image might be useful to understand the patients9 expectation and proper indication of the surgery. <h3>References</h3> Fujisaki K. Issues in nursing research of body image. Kango Kenkyu, 1996; 29 (4):307–319. Jorge RT, et al. Body image in patients with rheumatoid arthritis. Mod Rhematol, 2010; 20(5): 491–495. <h3>Disclosure of Interest</h3> None declared
OP0273 Effects of Tumor Necrosis Factor Alpha on Cytokine Secretion of Synovial Fluid-Derived Mesenchymal Stem Cell-like Cells
Authors: Z. Vereb, A. Váncsa, M. Pilling, G. Petrovski, Z. Szekanecz
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis is characterized by painful joint swelling, cartilage and bone destruction, chronic inflammation of the synovium (synovitis) with the accumulation of synovial fluid into the joint cavity. Within the synovial fluid the number of MSC-like cells (SYF-MSC) is increasing during the active phase of the disease. MSC are able to mediate immunosuppression via cell-cell contact and secreted factors respectively. <h3>Objectives</h3> Our goal was to screen the secreted proteins by SYF-MSCs under pro-inflammatory conditions. <h3>Methods</h3> Synovial fluid was harvested from patients with active RA (according to the Guidelines of the Helsinki Declaration). The isolated fluid/cells were cultured <i>in vitro,</i> their expression of well-known MSC markers as well as their differentiation potential was tested. SYF-MSCs were treated with human recombinant TNF alpha (TNFa) for 24 hour than the secreted cytokines were determined by high throughput protein array. <h3>Results</h3> SYF-MSCs secreted aggrecan, angiogenin, chitinase 3 like-1, Dkk-1, DPPIV, EMMPRIN, FGF-19, GM-CSF, IGFBP-3, IL-6, IL-17A, MCP-1, PDGF-AA, Pentraxin-3, Resistin, SDF-1α and Thrombospondin-1 under normal condition. Treatment by TNFa decreased the level of the secreted chitinase 3 like-1 (544003±56200.85; Pixel density, Mean±SD) and Dkk-1 (388062.5±10488.51) compared to untreated controls (721671.5±10434.77 and 705830±16013.14). Beside this phenomenon the pro-inflammatory provocation increased the secretion of IL-6 (from 79140±6940.96 to 615191±73256.26), MCP-1 (283985.5±25964.25 to 846348±81354.05), furthermore induced the release of IL-(8743315±71580.42) IL-24 (32189±29555.65) and RANTES (641698±26383.57). Unlike untreated cells no resistin, empirin and SDF-1 could be detected after TNFa exposure. <h3>Conclusions</h3> The <i>in vitro</i> data suggest that TNFa is able to turn SYF-MSCs to a pro-inflammatory phenotype, which may play a role in the inflammatory processes of RA prolonging the active phase of the disease. <h3>Disclosure of Interest</h3> None declared
Critical Role of flt3 in Fetal and Adult T Lymphopoiesis.
Authors: Ewa Sitnicka, Natalija Buza-Vidas, Henrik Ahlenius, Corrado M. Cilio, Christos Gekas, Jens M. Nygren, Christina T. Jensen, Marcus Svensson, William W. Agace, Sten Eirik W. Jacobsen
Journal: Blood (2005)
Comparative Efficacy Analysis of Busulfan Dose Intensity Between Two Reduced Intensity Conditioning Regimens (FB2 vs. FB4) for Allogeneic HCT for AML in First Complete Remission: A Report From the EBMT Acute Leukemia Working Party
Authors: Mohamed A Kharfan-Dabaja, Myriam Labopin, Ali Bazarbachi, Rose-Marie Hamljadi, Didier Blaise, Gérard Socié, Bruno Lioure, Arancha Bermudez, Dolores Caballero, Reuven Or, William Arcese, Nathalie Fegueux, Arnon Nagler, Mohamad Mohty
Journal: Blood (2012)
Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses
Authors: Joshua D Wallach, Patrick G Sullivan, John F Trepanowski, Ewout W Steyerberg, John P A Ioannidis
Journal: BMJ (2016)

<b>Objective</b>&nbsp;To evaluate the frequency, validity, and relevance of statistically significant (P&lt;0.05) sex-treatment interactions in randomized controlled trials in Cochrane meta-analyses. <b>Design</b>&nbsp;Meta-epidemiological study. <b>Data sources</b>&nbsp;Cochrane Database of Systematic Reviews (CDSR) and PubMed. <b>Eligibility criteria for study selection</b>&nbsp;Reviews published in the CDSR with sex-treatment subgroup analyses in the forest plots, using data from randomized controlled trials. <b>Data extraction</b>&nbsp;Information on the study design and sex subgroup data were extracted from reviews and forest plots that met inclusion criteria. For each statistically significant sex-treatment interaction, the potential for biological plausibility and clinical significance was considered. <b>Results</b>&nbsp;Among the 41 reviews with relevant data, there were 109 separate treatment-outcome analyses ("topics"). Among the 109 topics, eight (7%) had a statistically significant sex-treatment interaction. The 109 topics included 311 randomized controlled trials (162 with both sexes, 46 with males only, 103 with females only). Of the 162 individual randomized controlled trials that included both sexes, 15 (9%) had a statistically significant sex-treatment interaction. Of four topics where the first published randomized controlled trial had a statistically significant sex-treatment interaction, no meta-analyses that included other randomized controlled trials retained the statistical significance and no meta-analyses showed statistical significance when data from the first published randomized controlled trial were excluded. Of the eight statistically significant sex-treatment interactions from the overall analyses, only three were discussed by the CDSR reviewers for a potential impact on different clinical management for males compared with females. None of these topics had a sex-treatment interaction that influenced treatment recommendations in recent guidelines. UpToDate, an online physician-authored clinical decision support resource, suggested differential management of men and women for one of these sex-treatment interactions. <b>Conclusion</b>&nbsp;Statistically significant sex-treatment interactions are only slightly more frequent than what would be expected by chance and there is little evidence of subsequent corroboration or clinical relevance of sex-treatment interactions.
CD4+ T Cells in High-Risk MDS Patients Bear an Aberrant STAT Signaling Biosignature
Authors: Eleftheria Lamprianidou, Constantinos Tsatalas, Paraskevi Miltiades, Theodoros P. Vassilakopoulos, Sotirios G Papageorgiou, Athanasios G. Galanopoulos, Sofia Vakalopoulou, Vassilia Garypidou, Evangelia Nakou, Emmanuil Spanoudakis, Ioannis Kotsianidis
Journal: Blood (2014)
A Critical Role for STAT-3 Dependent Induction of Indoleamine 2, 3 Dioxygenase in Histone Deacetylase Inhibitors Mediated the Regulation of GVHD.
Authors: Yaping Sun, Elizabeth Weisiger, Tomomi Toubai, Charles Dinarello, James L. Ferrara, Pavan Reddy
Journal: Blood (2007)
PTU-121 Anorectal Dysfunction in Quiescent Inflammatory Bowel Disease: Is There A Role for Biofeedback Therapy?
Authors: DH Vasant, JK Limdi, K Solanki, NV Radhakrishnan
Journal: Gut (2016)

<h3>Introduction</h3> Despite optimal disease control and the absence of objective evidence of mucosal inflammation, symptoms of faecal incontinence (FI), increased stool frequency, urgency and tenesmus secondary to anorectal dysfunction can significantly reduce quality of life (QoL) in Inflammatory Bowel Disease (IBD) patients. Biofeedback therapy (BFT) is an established treatment for FI but its role in IBD patients with Anorectal dysfunction has not been explored. <h3>Methods</h3> In a retrospective study, we reviewed all patients with IBD referred for Anorectal Manometry (ARM) studies and BFT at our institution between 2009–2014 for FI.<sup>1</sup> Data confirming IBD quiescence was recorded with endoscopy, histology, radiography and biochemistry from all subjects. Additionally, IBD phenotypes and therapies, surgical and obstetric histories, baseline FI frequency, QoL scores (rated 0–10), ARM data and Endoanal Ultrasonography results (when available) were recorded. Patients were classified as responders or non-responders to BFT based on symptoms at follow-up. <h3>Results</h3> Nine IBD patients (median age 53, 7/9 female), with quiescent IBD (6/9 Crohn’s Disease (CD) and 3/9 Ulcerative Colitis (UC)), median baseline FI frequency 11.5/week and QoL score 6, completed in our Gastroenterologist-led BFT programme. In the CD cohort; 1/6 had previous anal fistula repair, 2/6 previous right hemicolectomy with ileal resection and 3/6 crohns colitis. In the UC group; 2/3 patients had proctitis/proctosigmoiditis and the other patient had ileo-anal pouch post-panproctocolectomy. Based on ARM findings; All patients had external sphincter weakness 9/9, whilst 6/9 had internal anal sphincter weakness and 2/9 met criteria for co-existing dyssynergic defecation. Following a mean of 3 BFT sessions; 8/9 (89%) patients reported improvement in FI symptoms with statistically significant improvement in FI frequency compared to baseline (Mann-Whitney <i>U</i> = 0.5, P = 0.003) and 5/9 (56%) reporting no FI episodes. <h3>Conclusion</h3> Our data in a heterogenous cohort of IBD patients with moderate QoL scores and FI despite disease quiescence, highlights the importance of considering referral for ARM studies after excluding active inflammation. BFT appears to be as effective in IBD patients as it is in non-IBD patients with FI and may have a role in improving QoL in these patients. <h3>Reference</h3> 1 Vasant D, Solanki K, Sharma R, <i>et al</i>. Ptu-180 predicting outcomes of biofeedback therapy for faecal incontinence – where ‘good’ practice makes perfect. <i>Gut</i> 2015;<b>64</b>:A142. <h3>Disclosure of Interest</h3> None Declared